scPharmaceuticals (SCPH) Q2 2024 earnings summary

Executive summary

• Net FUROSCIX revenue reached $8.1 million in Q2 2024, up 33% sequentially and from $1.6 million in Q2 2023, driven by increased adoption and commercial momentum.

• FDA approved FUROSCIX label expansion to NYHA Class IV heart failure in August 2024, broadening the addressable market.

• Announced positive PK/PD study results for the FUROSCIX autoinjector and FDA acceptance of sNDA for CKD indication, with a PDUFA date of March 6, 2025.

• Completed transformative financing of up to $175 million, including $75 million senior debt, $50 million synthetic royalty, and $50 million equity, extending cash runway through expected profitability.

• Net loss for Q2 2024 was $17.1 million, compared to $14.2 million in Q2 2023, reflecting higher SG&A and R&D expenses.

Financial highlights

• Q2 2024 product revenues were $8.1 million, up from $1.6 million in Q2 2023; cost of product revenues rose to $2.3 million from $0.4 million year-over-year.

• Net loss per share was $(0.44) for Q2 2024, compared to $(0.36) in Q2 2023.

• Cash and investments stood at $38.5 million as of June 30, 2024, excluding new financing proceeds.

• SG&A expenses increased to $17.5 million from $12.1 million year-over-year; R&D expenses were $2.7 million, down from $2.9 million.

• Weighted average shares outstanding were 38,984,745 for Q2 2024.

Outlook and guidance

• GTN discount expected to range from 10%-15% for the next two quarters, with a long-term target of 30%-35%.

• Fill rate improvements and Medicare copay caps in 2025 anticipated to positively impact net sales and patient access.

• Sales force expansion to 90 territories by Q3 2024, with plans for 130 reps upon CKD approval.

• Targeted sNDA submission for FUROSCIX autoinjector by year-end 2024; CKD label expansion PDUFA date set for March 6, 2025.

• Management expects continued operating losses as commercialization and R&D investments increase.